Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders

被引:114
作者
Diehl, Claudia J. [1 ]
Ciulli, Alessio [1 ]
机构
[1] Univ Dundee, Ctr Targeted Prot Degradat, Sch Life Sci, Dundee, Scotland
基金
欧洲研究理事会; 欧盟地平线“2020”; 英国生物技术与生命科学研究理事会;
关键词
PROTEIN-PROTEIN INTERACTIONS; UBIQUITIN-PROTEASOME PATHWAY; ANTIBODY-MEDIATED DELIVERY; TUMOR-SUPPRESSOR PROTEIN; HIF-ALPHA; CONFORMATIONAL CONTROL; STRUCTURAL INSIGHTS; ESTROGEN-RECEPTOR; DRUG DISCOVERY; FAK INHIBITORS;
D O I
10.1039/d2cs00387b
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The von Hippel-Lindau (VHL) Cullin RING E3 ligase is an essential enzyme in the ubiquitin-proteasome system that recruits substrates such as the hypoxia inducible factor for ubiquitination and subsequent proteasomal degradation. The ubiquitin-proteasome pathway can be hijacked toward non-native neo-substrate proteins using proteolysis targeting chimeras (PROTACs), bifunctional molecules designed to simultaneously bind to an E3 ligase and a target protein to induce target ubiquitination and degradation. The availability of high-quality small-molecule ligands with good binding affinity for E3 ligases is fundamental for PROTAC development. Lack of good E3 ligase ligands as starting points to develop PROTAC degraders was initially a stumbling block to the development of the field. Herein, the journey towards the design of small-molecule ligands binding to VHL is presented. We cover the structure-based design of VHL ligands, their application as inhibitors in their own right, and their implementation into rationally designed, potent PROTAC degraders of various target proteins. We highlight the key findings and learnings that have provided strong foundations for the remarkable development of targeted protein degradation, and that offer a blueprint for designing new ligands for E3 ligases beyond VHL.
引用
收藏
页码:8216 / 8257
页数:43
相关论文
共 215 条
[81]   Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway [J].
Kaelin, William G., Jr. ;
Ratcliffe, Peter J. .
MOLECULAR CELL, 2008, 30 (04) :393-402
[82]   von Hippel-Lindau disease [J].
Kaelin, William G., Jr. .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2007, 2 :145-173
[83]   Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase [J].
Kamura, T ;
Koepp, DM ;
Conrad, MN ;
Skowyra, D ;
Moreland, RJ ;
Iliopoulos, O ;
Lane, WS ;
Kaelin, WG ;
Elledge, SJ ;
Conaway, RC ;
Harper, JW ;
Conway, JW .
SCIENCE, 1999, 284 (5414) :657-661
[84]   A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity [J].
Khan, Sajid ;
Zhang, Xuan ;
Lv, Dongwen ;
Zhang, Qi ;
He, Yonghan ;
Zhang, Peiyi ;
Liu, Xingui ;
Thummuri, Dinesh ;
Yuan, Yaxia ;
Wiegand, Janet S. ;
Pei, Jing ;
Zhang, Weizhou ;
Sharma, Abhisheak ;
McCurdy, Christopher R. ;
Kuruvilla, Vinitha M. ;
Baran, Natalia ;
Ferrando, Adolfo A. ;
Kim, Yong-mi ;
Rogojina, Anna ;
Houghton, Peter J. ;
Huang, Guangcun ;
Hromas, Robert ;
Konopleva, Marina ;
Zheng, Guangrong ;
Zhou, Daohong .
NATURE MEDICINE, 2019, 25 (12) :1938-+
[85]   BINDING OF THE VONHIPPEL-LINDAU TUMOR-SUPPRESSOR PROTEIN TO ELONGIN-B AND ELONGIN-C [J].
KIBEL, A ;
ILIOPOULOS, O ;
DECAPRIO, JA ;
KAELIN, WG .
SCIENCE, 1995, 269 (5229) :1444-1446
[86]   Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera [J].
Kim, Kidae ;
Lee, Dong Ho ;
Park, Sungryul ;
Jo, Seung-Hyun ;
Ku, Bonsu ;
Park, Sung Goo ;
Park, Byoung Chul ;
Jeon, Yeong Uk ;
Ahn, Sunjoo ;
Kang, Chung Hyo ;
Hwang, Daehee ;
Chae, Sehyun ;
Ha, Jae Du ;
Kim, Sunhong ;
Hwang, Jong Yeon ;
Kim, Jeong-Hoon .
SCIENTIFIC REPORTS, 2019, 9 (1)
[87]   Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity [J].
Klein, Victoria G. ;
Bond, Adam G. ;
Craigon, Conner ;
Lokey, R. Scott ;
Ciulli, Alessio .
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (24) :18082-18101
[88]   Understanding and Improving the Membrane Permeability of VH032-Based PROTACs [J].
Klein, Victoria G. ;
Townsend, Chad E. ;
Testa, Andrea ;
Zengerle, Michael ;
Maniaci, Chiara ;
Hughes, Scott J. ;
Chan, Kwok-Ho ;
Ciulli, Alessio ;
Lokey, R. Scott .
ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (09) :1732-1738
[89]   Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2 [J].
Kobayashi, T ;
Cohen, P .
BIOCHEMICAL JOURNAL, 1999, 339 :319-328
[90]  
Kofink C., 2022, CHEMRXIV, DOI [10.26434/chemrxiv-2022-q63s3, DOI 10.26434/CHEMRXIV-2022-Q63S3]